SCHEMBL1352015

SCHEMBL1352015

Nc1ccc(-n2cnnc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
LMNA P02545 3/20 0.56
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
QPCT Q16769 1/20 0.45
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
ALDH1A1 P00352 6/20 0.38
HTT P42858 3/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 2/20 0.38
TP53 P04637 2/20 0.38
NPC1 O15118 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5798564 0.75 QPCT (0.52) CYP1A2CYP2C9QPCTKMT2AALDH1A1
SCHEMBL21923049 0.74 CYP1A2 (0.52) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL17690362 0.74 CYP1A2 (0.52) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL1186988 0.74 ENPP2 (0.56) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL15555209 0.74 CYP1A2 (0.52) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL6518759 0.74 CYP2C9 (0.58) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL12841347 0.74 CYP1A2 (0.52) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL10022377 0.73 NOTUM (0.55) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL7798192 0.73 CYP2C9 (0.47) MAPTLMNACYP1A2CYP2C9QPCT
SCHEMBL256624 0.72 CYP3A4 (0.52) MAPTLMNACYP1A2CYP2C9QPCT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117050460-B BN micropowder reinforced phenolic resin for copper-clad plate and preparation method thereof 江苏耀鸿电子有限公司 2024-01-23 CN claimed
CN-117050460-A BN micropowder reinforced phenolic resin for copper-clad plate and preparation method thereof 江苏耀鸿电子有限公司 2023-11-14 CN claimed
CN-117050460-B BN micropowder reinforced phenolic resin for copper-clad plate and preparation method thereof 江苏耀鸿电子有限公司 2024-01-23 CN disclosed
CN-117050460-A BN micropowder reinforced phenolic resin for copper-clad plate and preparation method thereof 江苏耀鸿电子有限公司 2023-11-14 CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-10428022-B2 Iminosugars useful for the treatment of viral diseases EMERGENT VIROLOGY LLC (US) 2019-10-01 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-6924302-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2005-08-02 US disclosed
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-04-22 US disclosed
EP-1355889-A1 SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-10-29 EP disclosed
WO-2002057240-A1 SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS ORTHO MC NEIL PHARMACEUTICAL, INC. (US) 2002-07-25 WO disclosed
US-6048878-A Substituted piperidine derivatives as selective agonists of 5-HT receptors MERCK SHARP & DOHME LTD. (GB) 2000-04-11 US disclosed
EP-0581538-B1 4-Substituted 1,2,4-triazole derivatives MERCK SHARP & DOHME (GB) 1999-03-03 EP disclosed
US-5854268-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME, LTD. (GB) 1998-12-29 US disclosed
US-5554629-A HEADACHES MERCK, SHARP & DOHME LTD. (GB) 1996-09-10 US disclosed
EP-0581538-A1 4-Substituted 1,2,4-triazole derivatives MERCK SHARP & DOHME LTD. (GB) 1994-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428022-B2 Iminosugars useful for the treatment of viral diseases GBA1, MAN2B1, GBA2 MAPT 3233/4885LMNA 1538/4885CYP1A2 1798/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK MAPT 470/4885LMNA 3015/4885CYP1A2 3832/4885
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors MAP2K2, PRKDC, MAP2K3 MAPT 1570/4885LMNA 3230/4885CYP1A2 4754/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885LMNA 3115/4885CYP1A2 3709/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885LMNA 3115/4885CYP1A2 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.